chikungunya

chikungunya
Name	Chikungunya
Field	Infectious disease
Symptoms	Fever, joint pain, rash
Complications	Chronic arthralgia, neurological complications
Onset	2–12 days
Duration	Acute 1–2 weeks; persistent joint pain months–years
Causes	Alphavirus (Togaviridae)
Risks	Aedes mosquitoes, travel to endemic areas, urbanization
Diagnosis	Serology, RT-PCR
Prevention	Mosquito control, vaccines under development
Treatment	Supportive care, analgesics, hydration
Frequency	Epidemic outbreaks in Africa, Asia, Americas

chikungunya Chikungunya is an acute viral illness characterized by sudden onset fever and severe polyarthralgia. It presents with rash and constitutional symptoms, often following travel to or residence in affected regions and outbreaks linked to vector expansion and urban transmission dynamics.

Signs and symptoms

Typical presentation includes high fever, incapacitating joint pain, and maculopapular rash often accompanied by headache and myalgia; these findings were described in clinical series from Tanzania, India, Thailand, Brazil, and Italy. Patients may develop chronic inflammatory arthritis, tenosynovitis, or persistent arthralgia prompting referrals to rheumatology clinics at centers such as Mayo Clinic, Johns Hopkins Hospital, and Aga Khan University Hospital. Neurological complications—encephalitis, Guillain–Barré syndrome, and meningoencephalitis—have been reported in cohort studies from Réunion, La Réunion, France, Colombia, and Puerto Rico, with critical care managed at institutions like Charité – Universitätsmedizin Berlin and Massachusetts General Hospital. Other manifestations include ocular disease (uveitis, retinitis) documented by teams at Aravind Eye Hospital and Wills Eye Hospital, and neonatal infection after peripartum transmission described in publications from Thailand and India.

Cause and transmission

The causative agent is an alphavirus in the family Togaviridae first isolated during investigations by researchers linked to expeditions to Tanzania and investigators from Centers for Disease Control and Prevention and Pasteur Institute. The virus cycles between primate reservoirs and anthrophilic vectors, principally Aedes aegypti and Aedes albopictus, implicating entomological research from Smithsonian Tropical Research Institute, Liverpool School of Tropical Medicine, and Institut Pasteur. Epidemic amplification occurs in urban settings via peridomestic transmission documented in Jakarta, Delhi, Mumbai, Fortaleza, and Guayaquil. Vertical transmission, nosocomial exposure, and transfusion-transmitted infections have been recorded in case reports from Sri Lanka, Réunion, Brazil, and Spain prompting guidelines from World Health Organization and Pan American Health Organization. Vector competence studies conducted at Rockefeller University, Institut Pasteur de Madagascar, and Universidad de São Paulo have elucidated mutations in the envelope gene associated with increased transmission by Aedes albopictus.

Diagnosis

Diagnosis relies on clinical suspicion combined with laboratory confirmation through serology (IgM, IgG) and molecular assays (RT-PCR) used by reference laboratories such as Centers for Disease Control and Prevention, Public Health England, and Institut Pasteur. Imaging and joint aspiration may be performed at specialist centers like Hospital for Special Surgery when chronic arthritis mimics conditions referred to American College of Rheumatology protocols. Differential diagnosis frequently includes dengue, Zika, malaria, and leptospirosis; comparisons are addressed in diagnostic guidelines from World Health Organization, Médecins Sans Frontières, and European Centre for Disease Prevention and Control. Commercial ELISA kits and in-house PCR assays validated by laboratories at Oswaldo Cruz Foundation and National Institutes of Health are commonly used for confirmation.

Prevention

Prevention emphasizes integrated vector management strategies deployed by public health agencies including World Health Organization, Pan American Health Organization, Centers for Disease Control and Prevention, and municipal programs in Singapore, Bangkok, Rio de Janeiro, Lagos, and Dar es Salaam. Personal protective measures recommended by National Health Service (UK), Health Canada, and Australian Department of Health include insect repellents and window screens; community interventions—source reduction, larviciding, and space spraying—are informed by entomological guidance from Walter Reed Army Institute of Research and London School of Hygiene & Tropical Medicine. Vaccine development programs at Valneva, Bharat Biotech, Themis Bioscience, National Institutes of Health, and Centro de Pesquisa em Vacinas are in various stages of clinical trials and regulatory review.

Treatment

Management is supportive: antipyretics, analgesics, oral hydration, and rest following treatment protocols used in emergency departments at Bellevue Hospital, Singapore General Hospital, and Hospital das Clínicas da Faculdade de Medicina da USP. Nonsteroidal anti-inflammatory drugs are commonly used after ruling out dengue co-infection per recommendations from World Health Organization and Pan American Health Organization; corticosteroids and disease-modifying antirheumatic drugs are considered for refractory chronic arthropathy in consultation with specialists at American College of Rheumatology centers. Hospitalization may be required for severe complications and supportive critical care is provided at tertiary centers like Royal Melbourne Hospital and Cleveland Clinic.

Epidemiology

Chikungunya has caused explosive epidemics across Africa, Asia, Europe, and the Americas with major outbreaks documented in Réunion (2005–2006), India (2006), Italy (2007), Caribbean islands (2013–2014), and Brazil (2014 onward). Surveillance data reported by World Health Organization, Pan American Health Organization, European Centre for Disease Prevention and Control, and national ministries of health in India, Brazil, Thailand, Colombia, and Mexico show cyclical re-emergence driven by vector expansion, urbanization, international travel, and viral evolution. Seroprevalence studies from Kenya, Madagascar, Cambodia, Venezuela, and Honduras reveal variable immunity levels; mathematical models developed at Imperial College London, Johns Hopkins Bloomberg School of Public Health, and École Polytechnique Fédérale de Lausanne estimate outbreak potential and inform control strategies.

Category:Arthropod-borne viral diseases